Skip to main content

FDA Approvals

FDA Approvals, In the News
October 28, 2019 – Oncology News & Updates
Read More
Breast Cancer, FDA Approvals, In the News, Multiple Myeloma, Pediatric Cancer, Oncology
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Read More
FDA Approvals, Multiple Myeloma, In the News, Oncology
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Read More
FDA Approvals
Enfortumab Vedotin Promising Third-Line Option for Metastatic Urothelial Cancer
Phoebe Starr
Phoebe Starr
Read More
FDA Approvals
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma
Wayne Kuznar
Read More
FDA Approvals
Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
Darzalex Combined with Revlimid and Dexamethasone New First-Line Regimen for Patients with Multiple Myeloma Ineligible for Transplant
Read More
FDA Approvals
Keytruda Receives New Indication for Metastatic Small-Cell Lung Cancer After Disease Progression
Read More
FDA Approvals
Keytruda First PD-1 Inhibitor Approved as First-Line Monotherapy for Patients with Metastatic or Unresectable Head and Neck Cancer
Read More
FDA Approvals
Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma
Read More
Page 20 of 53
Results 191 - 200 of 527